|Bid||17.28 x 0|
|Ask||17.56 x 0|
|Day's Range||16.82 - 18.03|
|52 Week Range||0.81 - 26.25|
|Beta (5Y Monthly)||0.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec. 21, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPA’s proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease. In a preclinical study using a SARS-CoV-2 hamster model, treatment with IPA’s TATX-03 resulted in complete clearance of detectable replication-competent virus from the lungs and throat of SARS-CoV-2 infected animals.
Canadian sleepwear brand Maylyn & Co. introduces their innovative, vegan, and luxury sleepwear that is ultra kind on the skin.
12, 2021 /CNW/ -TSX VENTURE COMPANIESAUMENTO CAPITAL VIII CORP.P") BULLETIN TYPE: New Listing-CPC-Shares BULLETIN DATE: February 12, 2021 TSX Venture Tier 2 CompanyThe Capital Pool Company's (the 'Company') Prospectus dated February 4, 2021, has been filed with and accepted by TSX Venture Exchange and the Ontario, British Columbia and Alberta Securities Commissions effective February 8, 2021, under the provisions of the respective Securities Acts.